{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T20:53:28Z","timestamp":1790801608281,"version":"4.1.0"},"reference-count":53,"publisher":"American Society for Microbiology","issue":"11","license":[{"start":{"date-parts":[[2016,11,1]],"date-time":"2016-11-01T00:00:00Z","timestamp":1477958400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"name":"Region Wallonne","award":["TEMOEXPAND"],"award-info":[{"award-number":["TEMOEXPAND"]}]},{"DOI":"10.13039\/501100004744","name":"Innoviris","doi-asserted-by":"publisher","award":["Doctiris"],"award-info":[{"award-number":["Doctiris"]}],"id":[{"id":"10.13039\/501100004744","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2016,11]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">Pseudomonas aeruginosa<\/jats:named-content>\n            is a major cause of morbidity and mortality in cystic fibrosis patients. This study compared the antimicrobial susceptibilities of 153\n            <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">P. aeruginosa<\/jats:named-content>\n            isolates from the United Kingdom (UK) (\n            <jats:italic>n =<\/jats:italic>\n            58), Belgium (\n            <jats:italic>n =<\/jats:italic>\n            44), and Germany (\n            <jats:italic>n =<\/jats:italic>\n            51) collected from 118 patients during routine visits over the period from 2006 to 2012. MICs were measured by broth microdilution. Genes encoding extended-spectrum \u03b2-lactamases (ESBL), metallo-\u03b2-lactamases, and carbapenemases were detected by PCR. Pulsed-field gel electrophoresis and multilocus sequence typing were performed on isolates resistant to \u22653 antibiotic classes among the penicillins\/cephalosporins, carbapenems, fluoroquinolones, aminoglycosides, and polymyxins. Based on EUCAST\/CLSI breakpoints, susceptibility rates were \u226430%\/\u226440% (penicillins, ceftazidime, amikacin, and ciprofloxacin), 44 to 48%\/48 to 63% (carbapenems), 72%\/72% (tobramycin), and 92%\/78% (colistin) independent of patient age. Sixty percent of strains were multidrug resistant (MDR; European Centre for Disease Prevention and Control criteria). Genes encoding the most prevalent ESBL (BEL, PER, GES, VEB, CTX-M, TEM, SHV, and OXA), metallo-\u03b2-lactamases (VIM, IMP, and NDM), or carbapenemases (OXA-48 and KPC) were not detected. The Liverpool epidemic strain (LES) was prevalent in UK isolates only (75% of MDR isolates). Four MDR sequence type 958 (ST958) isolates were found to be spread over the three countries. The other MDR clones were evidenced in \u22643 isolates and localized in a single country. A new sequence type (ST2254) was discovered in one MDR isolate in Germany. Clonal and nonclonal isolates with different susceptibility profiles were found in 20 patients. Thus, resistance and MDR are highly prevalent in routine isolates from 3 countries, with meropenem, tobramycin, and colistin remaining the most active drugs.\n          <\/jats:p>","DOI":"10.1128\/aac.01046-16","type":"journal-article","created":{"date-parts":[[2016,8,30]],"date-time":"2016-08-30T02:03:38Z","timestamp":1472522618000},"page":"6735-6741","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":47,"title":["Antimicrobial Susceptibility of Pseudomonas aeruginosa Isolated from Cystic Fibrosis Patients in Northern Europe"],"prefix":"10.1128","volume":"60","author":[{"given":"Muhammad-Hariri","family":"Mustafa","sequence":"first","affiliation":[{"name":"Pharmacologie cellulaire et mol\u00e9culaire, Louvain Drug Research Institute, Universit\u00e9 catholique de Louvain, Brussels, Belgium"},{"name":"SMB Laboratories, Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hussein","family":"Chalhoub","sequence":"additional","affiliation":[{"name":"Pharmacologie cellulaire et mol\u00e9culaire, Louvain Drug Research Institute, Universit\u00e9 catholique de Louvain, Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Denis","sequence":"additional","affiliation":[{"name":"H\u00f4pital Erasme\/H\u00f4pital des Enfants Malades, Universit\u00e9 libre de Bruxelles, Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariane","family":"Deplano","sequence":"additional","affiliation":[{"name":"H\u00f4pital Erasme\/H\u00f4pital des Enfants Malades, Universit\u00e9 libre de Bruxelles, Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Vergison","sequence":"additional","affiliation":[{"name":"H\u00f4pital Erasme\/H\u00f4pital des Enfants Malades, Universit\u00e9 libre de Bruxelles, Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hector","family":"Rodriguez-Villalobos","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Cliniques Universitaires Saint-Luc, Universit\u00e9 catholique de Louvain, Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael M.","family":"Tunney","sequence":"additional","affiliation":[{"name":"The Queen's University of Belfast, Belfast, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Stuart","family":"Elborn","sequence":"additional","affiliation":[{"name":"The Queen's University of Belfast, Belfast, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara C.","family":"Kahl","sequence":"additional","affiliation":[{"name":"University Hospital M\u00fcnster, M\u00fcnster, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamidou","family":"Traore","sequence":"additional","affiliation":[{"name":"SMB Laboratories, Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis","family":"Vanderbist","sequence":"additional","affiliation":[{"name":"SMB Laboratories, Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7121-3623","authenticated-orcid":false,"given":"Paul M.","family":"Tulkens","sequence":"additional","affiliation":[{"name":"Pharmacologie cellulaire et mol\u00e9culaire, Louvain Drug Research Institute, Universit\u00e9 catholique de Louvain, Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0052-7991","authenticated-orcid":false,"given":"Fran\u00e7oise","family":"Van Bambeke","sequence":"additional","affiliation":[{"name":"Pharmacologie cellulaire et mol\u00e9culaire, Louvain Drug Research Institute, Universit\u00e9 catholique de Louvain, Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)00576-6"},{"key":"e_1_3_3_3_2","unstructured":"Cystic Fibrosis Foundation. 2014. Patient registry 2014 annual data report. Cystic Fibrosis Foundatiohn Bethesda MD. https:\/\/www.cff.org\/2014_CFF_Annual_Data_Report_to_the_Center_Directors.pdf\/."},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2007.01681.x"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(96)05169-0"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2011.11.004"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0071001"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2015.08.002"},{"key":"e_1_3_3_9_2","volume-title":"CLSI document M100-S25","author":"Clinical and Laboratory Standards Institute","year":"2015","unstructured":"Clinical and Laboratory Standards Institute. 2015. Performance standards for antimicrobial susceptibility testing; 25th informational supplement. CLSI document M100-S25. Clinical and Laboratory Standards Institute, Wayne, PA."},{"key":"e_1_3_3_10_2","unstructured":"European Committee on Antimicrobial Susceptibility Testing. 2015. Breakpoint tables for interpretation of MICs and zone diameters version 5.0. http:\/\/www.eucast.org\/clinical_breakpoints\/."},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2011.03570.x"},{"key":"e_1_3_3_12_2","first-page":"411","article-title":"Molecular characterization of In50, a class 1 integron encoding the gene for the extended-spectrum beta-lactamase VEB-1 in Pseudomonas aeruginosa","volume":"176","author":"Naas T","year":"1999","unstructured":"Naas T, Poirel L, Karim A, Nordmann P. 1999. Molecular characterization of In50, a class 1 integron encoding the gene for the extended-spectrum beta-lactamase VEB-1 in Pseudomonas aeruginosa. FEMS Microbiol Lett 176:411\u2013419.","journal-title":"FEMS Microbiol Lett"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkq048"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00871-10"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.43.3.1198-1204.2005"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.42.12.5644-5649.2004"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2105-11-595"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/B978-012373944-5.00218-2"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1111\/resp.12714"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1111\/apm.12463"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkt115"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.02157-12"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.3892\/mmr.2014.2685"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.03218-13"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2010.08.005"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2015.07.010"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-015-0926-5"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2007.06.006"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1136\/thorax.58.9.794"},{"key":"e_1_3_3_30_2","unstructured":"European Committee on Antimicrobial Susceptibility Testing. 2015. Antimicrobial wild type distributions of microorganisms. http:\/\/www.eucast.org\/mic_distributions_and_ecoffs\/."},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/26.2.247"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.43.4.882"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1097\/PAT.0000000000000216"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2014.00138"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2010.12.003"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00816-09"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2012.00408"},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2008.02097.x"},{"key":"e_1_3_3_39_2","first-page":"CD004197","article-title":"Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis","volume":"11","author":"Langton Hewer SC","year":"2014","unstructured":"Langton Hewer SC, Smyth AR. 2014. Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis. Cochrane Database Syst Rev 11:CD004197.","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_3_3_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2009.03.001"},{"key":"e_1_3_3_41_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201207-1160OE"},{"key":"e_1_3_3_42_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2012.10.004"},{"key":"e_1_3_3_43_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2014.10.009"},{"key":"e_1_3_3_44_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0007740"},{"key":"e_1_3_3_45_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2013.04.003"},{"key":"e_1_3_3_46_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0060225"},{"key":"e_1_3_3_47_2","doi-asserted-by":"publisher","DOI":"10.1038\/srep07649"},{"key":"e_1_3_3_48_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.chom.2015.07.006"},{"key":"e_1_3_3_49_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0050731"},{"key":"e_1_3_3_50_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/31.6.919"},{"key":"e_1_3_3_51_2","doi-asserted-by":"publisher","DOI":"10.3109\/00365548.2010.509333"},{"key":"e_1_3_3_52_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2008.08.001"},{"key":"e_1_3_3_53_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dki146"},{"key":"e_1_3_3_54_2","article-title":"High-level resistance to meropenem in clinical isolates of Pseudomonas aeruginosa in the absence of carbapenemases: role of active efflux and porin alterations","author":"Chalhoub H","unstructured":"Chalhoub H, S\u00e1enz Y, Rodriguez-Villalobos H, Denis O, Kahl BC, Tulkens PM, Van Bambeke F. High-level resistance to meropenem in clinical isolates of Pseudomonas aeruginosa in the absence of carbapenemases: role of active efflux and porin alterations. Int J Antimicrob Agent, in press.","journal-title":"Int J Antimicrob Agent"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01046-16","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01046-16","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T20:34:28Z","timestamp":1645475668000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.01046-16"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11]]},"references-count":53,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2016,11]]}},"alternative-id":["10.1128\/AAC.01046-16"],"URL":"https:\/\/doi.org\/10.1128\/aac.01046-16","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,11]]},"assertion":[{"value":"2016-05-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-08-23","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-10-21","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}